Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD2: Patiromer in Children Under 12 Years of Age With Hyperkalemia
2023-505252-21-00Phase 2Authorised
- Sponsor
- Vifor Pharma
- Start
- Feb 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 21
01
Overview
Phase 2, open-label, single-arm trial of patiromer in hyperkalemia, sponsored by Vifor Pharma. Planned start Feb 2025; status: authorised.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2023-505252-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505252-21-00.